Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

From heart and kidney health to addiction reduction, GLP-1 drugs like Ozempic and Mounjaro may help with more than just ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

Zacks Investment Research Image Source ... shares of Novo Nordisk’s archrival in the obesity market space, Eli Lilly LLY, gained as its marketed drug, Zepbound (tirzepatide), continues to ...

Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s ...

Image Source: Zacks Investment ... shares of Novo Nordisk’s archrival in the obesity market space, Eli Lilly LLY, gained as its marketed drug, Zepbound (tirzepatide), continues to maintain ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

making it a go-to treatment not just for diabetes but also for obesity management. View Full Image The popularity of Wegovy, Ozempic, and other GLP-1 drugs lies in their ability to mimic natural ...

kudosstudio – stock.adobe.com Studies show that ... in adults with obesity. Bloomberg via Getty Images The drug can reportedly cause side effects like nausea, diarrhea, vomiting, constipation ...